These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 7992085)
41. Somatostatin and neoplastic pain. Kloke M Recent Results Cancer Res; 1993; 129():83-6. PubMed ID: 8102491 [No Abstract] [Full Text] [Related]
42. [International symposium on somatostatin analogues: fundamental aspects and clinical perspectives. Venice, Italy, 24-25 October 1997. Abstracts]. Ann Endocrinol (Paris); 1998; 59 Suppl 2():1-52. PubMed ID: 10065269 [No Abstract] [Full Text] [Related]
43. Somatostatin and the treatment of cancer. Pappas TN Ann Surg; 1991 Mar; 213(3):189. PubMed ID: 1671811 [No Abstract] [Full Text] [Related]
44. Somatostatin. Bloom SR; Polak JM Br Med J (Clin Res Ed); 1987 Aug; 295(6593):288-90. PubMed ID: 2888511 [No Abstract] [Full Text] [Related]
45. The Emergence of Somatostatin Antagonist-Based Theranostics: Paving the Road Toward Another Success? Imperiale A; Jha A; Meuter L; Nicolas GP; Taïeb D; Pacak K J Nucl Med; 2023 May; 64(5):682-684. PubMed ID: 36759198 [No Abstract] [Full Text] [Related]
46. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Samonakis DN; Notas G; Christodoulakis N; Kouroumalis EA Dig Dis Sci; 2008 Sep; 53(9):2359-65. PubMed ID: 18273705 [TBL] [Abstract][Full Text] [Related]
47. Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging. Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL Pituitary; 2007; 10(3):233-6. PubMed ID: 17541750 [TBL] [Abstract][Full Text] [Related]
48. The role of somatostatin analogs in the control of tumor growth. Lamberts SW; Reubi JC; Krenning EP Semin Oncol; 1994 Oct; 21(5 Suppl 13):61-4. PubMed ID: 7992085 [No Abstract] [Full Text] [Related]
49. Rationale for treating cancer with somatostatin analogs. Minuto F; Ferone D; Arvigo M; Barreca A J Endocrinol Invest; 2003; 26(8 Suppl):117-9. PubMed ID: 15233226 [No Abstract] [Full Text] [Related]
50. The effects of somatostatin analogs on biochemical parameters in acromegaly. Liuzzi A; Marzullo P J Endocrinol Invest; 2003; 26(8 Suppl):46-9. PubMed ID: 15233212 [No Abstract] [Full Text] [Related]
51. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843 [TBL] [Abstract][Full Text] [Related]
52. Somatostatin receptors and breast cancer. Cameron Smith M; Orlando C; Serio M; Maggi M J Endocrinol Invest; 2003; 26(8 Suppl):125-30. PubMed ID: 15233228 [No Abstract] [Full Text] [Related]
53. Role of somatostatin analogs in the management of rare tumors and diseases. Palmieri G; Montella L J Endocrinol Invest; 2003; 26(8 Suppl):89-91. PubMed ID: 15233221 [No Abstract] [Full Text] [Related]